Study summary
Semaglutide did not slow Alzheimer's
What was tested
Oral semaglutide, the diabetes and weight-loss drug, against placebo for two years in early Alzheimer's, in two large trials.
What they found
- Neither trial showed slower decline on the main scale at week 104.
- Blood and spinal-fluid markers of the disease improved, but that did not translate into slower progression.
What it means
Closes the most-watched attempt to repurpose a GLP-1 drug for people who already have symptoms.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.